TIEFENBACHER
Dead / Abandoned — Abandoned — failure to respond (as of 31 Mar 2022)
What this means for you
This application is over — abandoned 18 Mar 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 79296462
- Mark type
- Stylized text
- Filed
- 26 Aug 2020
- Abandoned
- 18 Mar 2022
- Attorney of record
- Jennifer Fraser
Goods and services
- Class 001 — Chemicals: Chemical, biological and biochemical products, preparations and reagents for scientific, research, laboratory and industrial purposes (other than for medical purposes); micro-organisms, proteins, polypeptides, nucleotides, nucleic acids, cell-lines and cells, in particular for scientific, research, laboratory and industrial purposes, other than for medical purposes; pharmaceutical, chemical, biological and biochemical products, preparations and reagents for researching and characterising diseases, for medical research and medicine development and for manufacturing medicines and pharmaceuticals; Chemical reagents for scientific use; biological diagnostic reagents for clinical or medical laboratory use; chemical preparations for general industrial manufacturing; Cells for scientific and research use; nucleic acid for laboratory use; biochemical, namely, polypeptides for in vitro research use; cultures of micro-organisms, other than for medical use; protein for industrial use, nucleotides for scientific and research use; Chemical additives for use in the manufacture of pharmaceuticals
- Class 005 — Pharmaceuticals: Medicinal specialities; generic medicines; pharmaceutical, chemical, biological and biochemical products, preparations and reagents, in particular for medical and diagnostic purposes; microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell-lines and cells, in particular for medical and diagnostic purposes, for investigation and characterisation of diseases, for medical research and development of medicines and for the manufacture of medicines and pharmaceuticals; sanitary preparations for medical purposes; dietetic preparations adapted for medical use; a full line of pharmaceuticals
- Class 042 — Scientific and technological services: Scientific and technological services, consultancy and research, in particular in the field of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for medicine development and for manufacturing medicines and pharmaceuticals; scientific and industrial research and development, in particular in the fields of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for development of medicines and for the manufacture of medicines and pharmaceuticals; investigation and development of medicines, diagnostic and analysis agents and therapy procedures (medical research); pharmaceutical, genealogical, bacteriological, biological, biochemical, chemical, molecular biological and forensic laboratories (other than medical consultancy); scientific experiments and providing scientific expertise in the fields of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for development of medicines and for the manufacture of medicines and pharmaceuticals; providing of technical information relating to generic medicines; services in relation to and advice on product development and quality maintenance; services of a medical and veterinary laboratory, in particular testing of medicines for others, development of new medicines; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Technical consulting in the field of pharmaceutical studies; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Pharmaceutical research services; pharmaceutical research and development; Technical research in the field of pharmaceutical studies; Research and development in the pharmaceutical and biotechnology fields; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals; conducting clinical trials for others; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; design and testing for new product development; chemical laboratories; Scientific and technological services, namely, scientific research, analysis, testing in the fields of pharmaceutical and drug development; scientific investigations for medical purposes; quality control for others; pharmaceutical drug development services; consultation in the private label manufacture and custom manufacture of pharmaceuticals and drugs
Owner
Prosecution history
- 24 Apr 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 31 Mar 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 31 Mar 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Apr 2022 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 31 Mar 2022 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 31 Mar 2022 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 23 Mar 2022 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 23 Mar 2022 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 17 Sept 2021 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 17 Sept 2021 — FINAL REFUSAL E-MAILED
- 17 Sept 2021 — FINAL REFUSAL WRITTEN
- 27 Jul 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Jul 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Jul 2021 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Jun 2021 — NEW REPRESENTATIVE AT IB RECEIVED